Skip to main content

Map17 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB400-151

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NB400-151
NB400-151SS

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Rat

Cited:

Mouse

Applications

Validated:

ICC/IF (Negative), Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

This product is unpurified. The exact concentration of antibody is not quantifiable.

Product Specifications

Immunogen

A synthetic peptide made to the C-terminus of mouse Map17. [UniProt# Q9CQH0]

Localization

Membrane-associated

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

14 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Applications for Map17 Antibody

Application
Recommended Usage

Western Blot

1:1000
Application Notes
This Map17 antibody is useful for Western blot, where a major band of ~14 kDa is detected. Minor cross-reacting bands are visible at higher molecular weights. This antibody is not applicable for ICC/IF.

The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Formulation, Preparation, and Storage

Purification

Unpurified

Formulation

Whole antisera

Preservative

0.05% Sodium Azide

Concentration

This product is unpurified. The exact concentration of antibody is not quantifiable.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

Background: Map17

MAP17 (17 kD membrane-associated protein) is a small non-glycosylated protein which localize to plasma membrane as well as Golgi apparatus, and interacts with several PDZ domain-containing proteins such as NHeRF proteins, NaPi-IIa, and NHe3. Overexpression of MAP17 in OK cells (opossum kidney epithelial cells) participates in NaPi-IIa internalization to the trans-Golgi network. In mouse, MAP17 overexpression in liver resulted in PDZK1 (NHeRF3) hepatic deficiency, suggesting MAP17's role in endogenous regulation of PDZK1 turnover. MAP17 acts as an atypical anchoring site for PDZK1 and interacts with NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells, wherein its physiological role is not well known, but it does stimulate specific Na-dependent transport of mannose and glucose in Xenopus oocytes as well as in human cancer cells. MAP17 is overexpressed in a variety of human carcinomas and its overexpression strongly correlates with ROS overproduction as well as tumoral progression characterized by decreased apoptotic sensitivity with enhanced proliferation and migration in prostate, breast, ovarian cancer etc. This increase in ROS as well as tumor aggressiveness relies largely on its PDZ-binding domain as disruption of this sequence by point mutations has been shown to abolish MAP17's ability to enhance ROS production and tumorigenesis.

Alternate Names

17 kDa membrane-associated protein, DD96, MAP17epithelial protein up-regulated in carcinoma, membrane associated protein 17, membrane-associated protein 17, PDZK1 interacting protein 1, PDZK1-interacting protein 1, Protein DD96, RP1-18D14.5, SPAP

Entrez Gene IDs

10158 (Human); 67182 (Mouse); 81916 (Rat)

Gene Symbol

PDZK1IP1

UniProt

Additional Map17 Products

Product Documents for Map17 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Map17 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...